GSK3845097

DRUG2 trials

Sponsors

Adaptimmune

Conditions

Neoplasms

Phase 1

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

TerminatedNCT04526509

AdaptimmuneNeoplasms

Start: 2020-12-21End: 2023-06-08Updated: 2024-11-26

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

TerminatedNCT05943990

AdaptimmuneNeoplasms

Start: 2020-12-21End: 2022-10-24Updated: 2024-11-13

Related Papers

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma.

2022-09-0845 citations

ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].

Journal of Clinical Oncology2022-06-013 citations

Abstract CT219: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer

Cancer Research2021-07-011 citations

Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).

Journal of Clinical Oncology2021-05-201 citations